These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 21670560)

  • 1. Significance of a novel apolipoprotein E variant, ApoE Osaka/Kurashiki, in lipoprotein glomerulopathy.
    Saito T; Matsunaga A
    J Atheroscler Thromb; 2011; 18(6):542-3. PubMed ID: 21670560
    [No Abstract]   [Full Text] [Related]  

  • 2. A novel mutation ApoE2 Kurashiki (R158P) in a patient with lipoprotein glomerulopathy.
    Tokura T; Itano S; Kobayashi S; Kuwabara A; Fujimoto S; Horike H; Satoh M; Komai N; Tomita N; Matsunaga A; Saito T; Sasaki T; Kashihara N
    J Atheroscler Thromb; 2011; 18(6):536-41. PubMed ID: 21467726
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A novel apolipoprotein E mutation, ApoE Osaka (Arg158 Pro), in a dyslipidemic patient with lipoprotein glomerulopathy.
    Mitani A; Ishigami M; Watase K; Minakata T; Yamamura T
    J Atheroscler Thromb; 2011; 18(6):531-5. PubMed ID: 21325775
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A new apolipoprotein E mutation, apoE Las Vegas, in a European-American with lipoprotein glomerulopathy.
    Bomback AS; Song H; D'Agati VD; Cohen SD; Neal A; Appel GB; Rovin BH
    Nephrol Dial Transplant; 2010 Oct; 25(10):3442-6. PubMed ID: 20624773
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Plasma level and genetic variation of apolipoprotein E in patients with lipoprotein glomerulopathy.
    Zhang B; Liu ZH; Zeng CH; Zheng JM; Chen HP; Zhou H; Li LS
    Chin Med J (Engl); 2005 Apr; 118(7):555-60. PubMed ID: 15820086
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lipoprotein glomerulopathy associated with the Osaka/Kurashiki APOE variant: two cases identified in Latin America.
    da Silveira-Neto JN; de Oliveira Ahn GJ; de Menezes Neves PDM; Baptista VAF; de Almeida Araújo S; Wanderley DC; Watanabe A; Watanabe EH; Murai NM; Bertollo EMG; Vieira-Neto OM; Dantas M; de Antônio SR; Costa RS; Baptista MASF; Moysés-Neto M; Onuchic LF
    Diagn Pathol; 2021 Jul; 16(1):65. PubMed ID: 34311745
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel glomerular lipoprotein deposits associated with apolipoprotein E2 homozygosity.
    Sakatsume M; Kadomura M; Sakata I; Imai N; Kondo D; Osawa Y; Shimada H; Ueno M; Miida T; Nishi S; Arakawa M; Gejyo F
    Kidney Int; 2001 May; 59(5):1911-8. PubMed ID: 11318963
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Discovery of a Chinese Tibetan patient with lipoprotein glomerulopathy due to APOE Osaka/Kurashiki variant].
    Yang Z; Wu H; Hu Z
    Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2020 Feb; 37(2):166-169. PubMed ID: 32034747
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Lipoprotein glomerulopathy].
    Oikawa S
    Nihon Rinsho; 2001 Mar; 59 Suppl 3():353-60. PubMed ID: 11347095
    [No Abstract]   [Full Text] [Related]  

  • 10. Topics in lipoprotein glomerulopathy: an overview.
    Saito T; Matsunaga A; Ito K; Nakashima H
    Clin Exp Nephrol; 2014 Apr; 18(2):214-7. PubMed ID: 24149835
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A novel apolipoprotein E mutation, E2 (Arg25Cys), in lipoprotein glomerulopathy.
    Matsunaga A; Sasaki J; Komatsu T; Kanatsu K; Tsuji E; Moriyama K; Koga T; Arakawa K; Oikawa S; Saito T; Kita T; Doi T
    Kidney Int; 1999 Aug; 56(2):421-7. PubMed ID: 10432380
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lipoprotein glomerulopathy in China.
    Chen Y
    Clin Exp Nephrol; 2014 Apr; 18(2):218-9. PubMed ID: 24165683
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A novel apolipoprotein E mutation, ApoE Tsukuba (Arg 114 Cys), in lipoprotein glomerulopathy.
    Hagiwara M; Yamagata K; Matsunaga T; Arakawa Y; Usui J; Shimizu Y; Aita K; Nagata M; Koyama A; Zhang B; Mastunaga A; Saku K; Saito T
    Nephrol Dial Transplant; 2008 Jan; 23(1):381-4. PubMed ID: 17967799
    [No Abstract]   [Full Text] [Related]  

  • 14. Lipoprotein glomerulopathy and its pathogenesis.
    Saito T; Oikawa S; Sato H; Chiba J
    Contrib Nephrol; 1997; 120():30-8. PubMed ID: 9257045
    [No Abstract]   [Full Text] [Related]  

  • 15. Apolipoprotein E-related glomerular disorders.
    Saito T; Matsunaga A; Fukunaga M; Nagahama K; Hara S; Muso E
    Kidney Int; 2020 Feb; 97(2):279-288. PubMed ID: 31874799
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Apolipoprotein E2/E5 variants in lipoprotein glomerulopathy recurred in transplanted kidney.
    Miyata T; Sugiyama S; Nangaku M; Suzuki D; Uragami K; Inagi R; Sakai H; Kurokawa K
    J Am Soc Nephrol; 1999 Jul; 10(7):1590-5. PubMed ID: 10405216
    [TBL] [Abstract][Full Text] [Related]  

  • 17. APOE Kyoto mutation in European Americans with lipoprotein glomerulopathy.
    Rovin BH; Roncone D; McKinley A; Nadasdy T; Korbet SM; Schwartz MM
    N Engl J Med; 2007 Dec; 357(24):2522-4. PubMed ID: 18077821
    [No Abstract]   [Full Text] [Related]  

  • 18. Etiological significance of apolipoprotein E mutations in lipoprotein glomerulopathy.
    Saito T; Ishigaki Y; Oikawa S; Yamamoto TT
    Trends Cardiovasc Med; 2002 Feb; 12(2):67-70. PubMed ID: 11852253
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A rare case of lipoprotein glomerulopathy in a white man: an emerging entity in Asia, rare in the white population.
    Boumendjel R; Papari M; Gonzalez M
    Arch Pathol Lab Med; 2010 Feb; 134(2):279-82. PubMed ID: 20121619
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Disappearance of intraglomerular lipoprotein thrombi and marked improvement of nephrotic syndrome by bezafibrate treatment in a patient with lipoprotein glomerulopathy.
    Arai T; Yamashita S; Yamane M; Manabe N; Matsuzaki T; Kiriyama K; Kanayama Y; Himeno S; Matsuzawa Y
    Atherosclerosis; 2003 Aug; 169(2):293-9. PubMed ID: 12921981
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.